Brief: European Commission Approves Subcutaneous Rybrevant® (Amivantamab)
07/04/2025 14:30
April 7 (Reuters) - Halozyme Therapeutics Inc HALO.O: EUROPEAN COMMISSION APPROVES SUBCUTANEOUS RYBREVANT® (AMIVANTAMAB) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF PATIENTS WITH ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER Source text: ID:nPn1JVNCGa Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets